Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ATTO with free AI briefings, catalyst countdowns, and dilution alerts.

ATTO · Attovia Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$395.9M Cash on Hand
58.2mo Cash Runway
Follow ATTO by email Get an email when ATTO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ATTO, unsubscribe in one click. Privacy

📣 What ATTO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ATTO-1310 Chronic Pruritus of Unknown Origin Phase 2 · NCT07833306 Not yet recruiting
ATTO-1091 Ulcerative Colitis (UC) Phase 1 · NCT07819799 Not yet recruiting
ATTO-3712 Normal Volunteers Phase 1 · NCT07205081 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ATTO holds $395.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.4M/quarter from operations, an estimated runway of 58.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATTO files for a raise →

👥 Who Owns ATTO

Insiders 49% Institutions (14 holders) 37.7% Public and other holders 13.3%
HolderTypeShares% of sharesAs of
Frazier Life Sciences XI, L.P.
10% owner
Insider 6,154,213 13.46% 2026-08-06
venBio Global Strategic Fund IV, L.P.
10% owner
Insider 4,181,366 9.15% 2026-09-30
Alamar HoldCo, LLC
10% owner
Insider 3,229,278 7.06% 2026-09-30
Deep Track Capital, LP Institution (13G, 5%+) 3,207,138 7.02% 2026-08-05
GOLDMAN SACHS GROUP INC
Former 10% Owner · +105,807 options
Insider 3,041,575 6.65% 2026-09-30
Colin Walsh
Director · +105,807 options
Includes shares also reported by GOLDMAN SACHS GROUP INC, counted once
Insider 3,020,632 6.61% 2026-08-05
Redmile Group, LLC
10% owner
Insider 2,165,708 4.74% 2026-08-06
Deep Track Biotechnology Master Fund, Lt
10% owner
Insider 1,957,138 4.28% 2026-08-06
Sanofi
10% owner
Insider 1,082,855 2.37% 2026-08-06
Tao Fu
President and CEO, Director · +538,300 options
Insider 333,268 0.73% 2026-08-04
Attovia Therapeutics, Inc.
Chief Financial Officer · +140,000 options
Includes shares also reported by Tao Fu, counted once
Insider 333,268 0.73% 2026-08-04
Petter Veiby
Chief Scientific Officer · +140,000 options
Insider 104,951 0.23% 2026-08-04

Share count 45,712,536 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ATTO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATTO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.